Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND
December 08, 2022 07:30 ET
|
Cytokinetics, Incorporated
Analysis from FORTITUDE-ALS Shows Predicted Survival Risk Score Strongly Correlated with Decline in ALSFRS-R Findings Suggest Inclusion Criteria for COURAGE-ALS Will Enrich for the Enrollment of...
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136
December 07, 2022 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized,...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2022 it granted stock options to purchase an aggregate...
Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND
December 01, 2022 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one poster presentation at the Virtual 33rd International Symposium on...
Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022
November 07, 2022 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from two additional analyses from GALACTIC-HF (Global Approach to...
Cytokinetics Reports Third Quarter 2022 Financial Results
November 03, 2022 16:00 ET
|
Cytokinetics, Incorporated
Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil on December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 SEQUOIA-HCM Continuing with Results Expected in 2H 2023;...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2022 it granted stock options to purchase an aggregate of...
Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022
October 31, 2022 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming poster presentations at the American Heart Association...
Cytokinetics to Announce Third Quarter Results on November 3, 2022
October 20, 2022 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2022 at...
Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis
October 10, 2022 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring Committee (DMC) for COURAGE-ALS (Clinical Outcomes...